Colchicine for acute and chronic coronary syndromes

  title={Colchicine for acute and chronic coronary syndromes},
  author={M. Imazio and A. Andreis and A. Brucato and Y. Adler and G. D. De Ferrari},
  pages={1555 - 1560}
Colchicine is an ancient drug, traditionally used for the treatment and prevention of gouty attacks; it has become standard of treatment for pericarditis with a potential role in the treatment of coronary artery disease. Atherosclerotic plaque formation, progression, destabilisation and rupture are influenced by active proinflammatory cytokines interleukin (IL)-1β and IL-18 that are generated in the active forms by inflammasomes, which are cytosolic multiprotein oligomers of the innate immune… Expand
Colchicine and the heart
The aim of this review is to summarize the contemporary data supporting the efficacy and safety of colchicine in patients with CV disease. Expand
Colchicine for the Treatment of Coronary Artery Disease.
These considerations provide a conceptual framework for the use of anti-inflammatory therapies in patients with chronic coronary syndrome or ACS and reappraise the available literature on colchicine and coronary artery disease to assess the likelihood that it might become part of the therapeutic armamentarium of this condition. Expand
Colchicine efficacy and safety for the treatment of cardiovascular diseases
Colchicine is efficacious and safe for the treatment of cardiovascular diseases and associated with increased risk of gastrointestinal CRAEs and drug discontinuation. Expand
Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes
In this review, the successes and existing doubts of interleukin 1β antibodies, interLEukin 6 receptor antagonists, and colchicine in the anti-inflammatory treatment of coronary atherosclerotic heart disease are summarized. Expand
Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease.
It is demonstrated that colchicine treatment may reduce the risk of future cardiovascular events in CAD patients and is associated with a significantly lower incidence of major adverse cardiovascular events compared with placebo or no treatment. Expand
Anti-inflammatory Therapy in Atherosclerosis: The Past and the Future
Since 1847 when Vogel, an eminent German pathologist, first observed that cholesterol was present in arterial plaques, atherosclerosis (AS) has been regarded as a cholesterol storage diseaseExpand
Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients.
The use of colchicine in patients with CAD is safe and efficacious for MACCE prevention and gastrointestinal DAEs and discontinuation may be prevented with a lower daily dose. Expand
Colchicine protects against cartilage degeneration by inhibiting MMP13 expression via PLC-γ1 phosphorylation.
  • K. Takeuchi, H. Ogawa, +8 authors H. Akiyama
  • Medicine
  • Osteoarthritis and cartilage
  • 2021
OBJECTIVE Low molecular weight compounds that reduce the expression of MMP13 at the mRNA level might serve as disease-modifying osteoarthritis (OA) drugs (DMOADs). The objective of this study was toExpand
Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis
To evaluate the efficacy and safety of colchicine for secondary prevention of coronary heart disease (CHD), relevant randomized controlled trials (RCTs) were identified by searching several databasesExpand
Vaccination in Atherosclerosis
The current vaccination strategies against atherosclerosis, supposed mechanisms of action, therapeutic potential, and the challenges that must be overcome in translating this idea into clinical practice are discussed. Expand


Colchicine and the heart: pushing the envelope.
The biochemical characteristics, mechanism of action and side-effects of colchicine are presented, as well as what is currently known about the promising role of col chicine in cardiovascular medicine beyond pericardial disease are examined. Expand
Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome
Assessment of the local cardiac production of inflammatory cytokines in patients with acute coronary syndromes (ACS), stable coronary artery disease and in controls determined whether acute administration of colchicine inhibits their production, and short-term colchichine administration rapidly and significantly reduces levels of these cytokines. Expand
Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study.
It is reported for the first time that short-term colchicine therapy significantly reduces the local production of coronary chemokines, in part by attenuating production of these mediators by monocytes. Expand
Mechanism of action of colchicine in the treatment of gout.
The multimodal mechanism of action of colchicine suggests potential efficacy of col chicine in other comorbid conditions associated with gout and other chronic inflammatory diseases, such as osteoarthritis and cardiovascular disease. Expand
The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
The role of monocytes/macrophages and neutrophils in Atherosclerosis is described, mechanisms of activation of the NLRP3 inflammasome in the setting of atherosclerosis-associated inflammation are outlined and potential therapies that specifically target the NL RP3 infammasome and/or its downstream mediators in atheros sclerosis are discussed. Expand
COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.
The effect of colchicine on inflammation in the context of STEMI could not be demonstrated, and further larger studies may clarify the impact of col chicine in acute myocardial infarction. Expand
Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease.
Administration of low-dose colchicine did not improve endothelial function in patients with CAD, but exploratory analysis suggested that endothelium function is significantly improved in Patients with leukocyte activation. Expand
Colchicine for cardiovascular medicine.
The essential pharmacology is reviewed and potential efficacy and safety of colchicine for new emerging cardiovascular indications are explored. Expand
Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout
In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take col chicine. Expand
Low-dose colchicine for secondary prevention of cardiovascular disease.
Colchicine 0.5 mg/day administered in addition to statins and other standard secondary prevention therapies appeared effective for the prevention of cardiovascular events in patients with stable coronary disease. Expand